Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

REprogramming Pancreatic Alpha-cells for Insulin production Restoration in diabetes

Project description

Reprogramming diabetic cells to produce insulin

Diabetes is caused by the inability of the pancreas to produce sufficient insulin. This leads to chronically high blood sugar and severe long-term complications. Current treatments manage symptoms, but do not restore the body’s natural control of glucose. The ERC-funded REPAIR project aims to develop an innovative therapy by converting existing pancreatic cells into new insulin-producing cells. Unlike insulin-producing beta cells, other islet cells, such as alpha cells, remain abundant in diabetic patients. Building on experimental evidence, the project will develop a drug-based approach using approved small molecules to reprogramme pancreatic alpha cells to produce insulin. If successful, this strategy could offer a safe, durable, and clinically realistic cure for diabetes.

Objective

Diabetes affects some 500 million people worldwide (estimated 700 million by 2045), causing over one million deaths annually. The disease results from the loss / dysfunction of pancreatic islet insulin-producing β-cells, leading to chronic hyperglycemia and severe complications. Current treatments are symptomatic and fail to restore long-term glucose regulation, stressing the need for a transformative curative approach.
Our proposal leverages α-cell reprogramming as a novel therapy for the restoration of insulin-production in situ, i.e. in the pancreas of diabetics. Islet α-cells remain abundant in diabetic patients and, along with δ- and γ-cells, they possess intrinsic plasticity, meaning that they can “learn” to produce insulin (Nature, 2010 & 2014; Diab Obes Metab, 2016; Nat Cell Biol, 2018; Nat Comm, 2021). Recently, we have shown that if all islet non-β-cells were converted into insulin producers, the islets containing only insulin-producing cells would be perfectly viable and functional, keeping optimal glucose homeostasis (Nat Metab, 2024). We have also reported that genetically reprogrammed human α-cells can secrete insulin and restore normal glucose levels when transplanted to diabetic mice (Nature, 2019). These findings establish islet non-β-cell reprogramming as a viable innovative strategy for diabetes cure.
Here, we aim at developing a first-in-class, non-genetic therapy to induce in situ α-cell reprogramming using small molecules. From a targeted screening we identified six FDA-approved compounds that induce insulin expression above a reprogramming threshold in purified α-cells from 2 donors. We will now explore their mechanism of action re the functional conversion and conduct preclinical studies in healthy and diabetic mice to assess reprogramming efficiency in both endogenous and transplanted human cells. If successful, this approach could transform diabetes therapy, offering a safe and clinically viable alternative to current treatments.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

UNIVERSITE DE GENEVE
Net EU contribution
€ 150 000,00
Address
RUE DU GENERAL DUFOUR 24
1211 Geneve
Switzerland
Region
Schweiz/Suisse/Svizzera Région lémanique Genève
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)